MFAP4 promotes cell prognosis of non-small cell lung cancer through the inhibition of ferroptosis by FAK

Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for 80% of lung cancer types, with a high metastasis rate and mortality. Here, this experiment investigated the effects of MFAP4 in NSCLC and its molecular mechanisms of ferroptosis in NSCLC. Patients with NSCLC and normal volunteer were obtained from our hospital. The mRNA and protein expression levels of MFAP4 were upregulated in a mouse model of NSCLC. MFAP4 expression levels in cancer cells of NSCLC model through Single Cell Analysis. Sh-MFAP4 reduced cancer growth, and increased Mitochondrial oxidation-induced ferroptosis in mice model of cancer. MFAP4 promoted cell growth, and reduced Mitochondrial oxidation of NSCLC. Si-MFAP4 increased Mitochondrial oxidation of NSCLC. MFAP4 induced FAK expression of NSCLC through the inhibition of FAK Ubiquitination. The m6A/METTL3 modifies MFAP4 expression stability in model of NSCLC by YTHDF1. In conclusion, MFAP4 induced FAK expression to reduce Mitochondrial oxidation-induced ferroptosis of NSCLC model through the inhibition of FAK Ubiquitination. Targeting MFAP4 is thus a potentially effective therapeutic strategy for patients with NSCLC or other cancer.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Medicine
Published
2026-03-08
DOI
https://doi.org/10.1007/s10238-026-02104-8
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MFAP4 promotes cell prognosis of non-small cell lung cancer through the inhibition of ferroptosis by FAK

X. Li, Youcai Zhu, Yonghua Min, Zhanqiang Zhai et al.
Clinical and Experimental Medicine
RNA modifications and cancer
article

MFAP4 promotes cell prognosis of non-small cell lung cancer through the inhibition of ferroptosis by FAK

X. Li, Youcai Zhu, Yonghua Min, Zhanqiang Zhai, Chunwei Xu
article en

Abstract

Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for 80% of lung cancer types, with a high metastasis rate and mortality. Here, this experiment investigated the effects of MFAP4 in NSCLC and its molecular mechanisms of ferroptosis in NSCLC. Patients with NSCLC and normal volunteer were obtained from our hospital. The mRNA and protein expression levels of MFAP4 were upregulated in a mouse model of NSCLC. MFAP4 expression levels in cancer cells of NSCLC model through Single Cell Analysis. Sh-MFAP4 reduced cancer growth, and increased Mitochondrial oxidation-induced ferroptosis in mice model of cancer. MFAP4 promoted cell growth, and reduced Mitochondrial oxidation of NSCLC. Si-MFAP4 increased Mitochondrial oxidation of NSCLC. MFAP4 induced FAK expression of NSCLC through the inhibition of FAK Ubiquitination. The m6A/METTL3 modifies MFAP4 expression stability in model of NSCLC by YTHDF1. In conclusion, MFAP4 induced FAK expression to reduce Mitochondrial oxidation-induced ferroptosis of NSCLC model through the inhibition of FAK Ubiquitination. Targeting MFAP4 is thus a potentially effective therapeutic strategy for patients with NSCLC or other cancer.

Clinical and Experimental MedicineVol. 26(1)
Jiaxing University (CN), Zhejiang Cancer Hospital (CN), First Hospital of Jiaxing (CN)
Good health and well-being
Openalex Percentile: Top 29%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

MFAP4 promotes cell prognosis of non-small cell lung cancer through the inhibition of ferroptosis by FAK — X. Li, Youcai Zhu, et al. · Clinical and Experimental Medicine (2026) | TGRS Research Map | TGRS